Fenofibrate capsules are usually not recommended for chronic kidney disease stage II. Fenofibrate is mainly used for the treatment of hypercholesterolemia, endogenous hypertriglyceridemia, etc. in adults with unsatisfactory effect of diet control therapy. It is contraindicated for allergy to this drug, hepatic insufficiency, renal insufficiency, children, pregnancy, breastfeeding and so on. Therefore, oral administration of Fenofibrate is not recommended for patients with chronic kidney disease stage II. In addition, Fenofibrate may cause muscle dysfunction such as diffuse pain, muscle weakness, tenderness sensation, etc. and rare severe rhabdomyolysis, and may also cause gastric or intestinal digestive dysfunction, transaminase elevation, skin rash, urticaria and other adverse reactions. If patients need to apply fenofibrate, it is recommended to use the drug under the guidance of a doctor, not blindly self-medication to avoid adverse effects.